Oligonucleotide Synthesis market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.
Oligonucleotide Synthesis Market Dynamics: Impact Analysis 1. Attractive Opportunities in the Market
2. Increasing Use of Synthesized Oligos in Molecular Diagnostics
3. Clinical Applications
4. R&D Expenditure in Pharmaceutical and Biotechnology Companies
The global oligonucleotide synthesis market is projected to reach USD 8.2 billion by 2024 from USD 4.3 billion in 2019, at a CAGR of 13.7% Key Questions Addressed in The Report: 1. Who are the top 10 players operating in the global Oligonucleotide Synthesis market?
2. What are the drivers, restraints, opportunities, and challenges in the Oligonucleotide Synthesis Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of Oligonucleotide Synthesis in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?
Therapeutic applications: The therapeutic applications segment, which is further segmented into RNAi oligonucleotide-based therapies, DNA & antisense oligonucleotide-based therapies, and CpG oligonucleotide-based therapies, is estimated to witness the highest growth during the forecast period. This can primarily be attributed to the investments made by companies to explore the therapeutic applications of oligos. Also, from 2016 to 2018, more than five oligonucleotide-based therapies were approved by the FDA.
In 2018, these oligonucleotide-based drugs generated a revenue of ~USD 2 billion. Apart from this, there are a couple of oligonucleotide-based drugs in Phase III and FDA review, and these drugs might be launched in the next five years and may positively impact this market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
Oligonucleotide-based drugs: The synthesized oligos market, by product, is segmented into oligonucleotide-based drugs, primers, probes, large-scale synthesized oligos, intermediate-scale synthesized oligos, and linkers and adaptors. Of these, oligonucleotide-based accounted for over 50% of the synthesized oligos market share in 2018. This segment is also estimated to grow at the highest CAGR during the forecast period due to the increasing demand for oligonucleotide-based drugs and the influx of new customers in the oligo drug development arena.
This market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.
Know more about the oligonucleotide synthesis market Industry Segments, Growth, Size, Key Players Analysis. Regional Growth Analysis of Oligonucleotide Synthesis:
The oligonucleotide synthesis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the oligonucleotide synthesis market majorly due to the availability of funds for research from various public- and private-sector organizations in the region and the focus of various prominent players on strengthening their presence in North America.
Know about the Growth Opportunities of Oligonucleotide Synthesis Market in Europe,the Asia Pacific, Latin America, and the Middle East & Africa.
Request Sample Pages:
Key Players in Market:
The prominent players operating in the oligonucleotide synthesis industry include BioAutomation Corporation (US), LGC Biosearch Technologies (US), Eurogentec (Belgium), GeneDesign, Inc. (Japan), Sarepta Therapeutics (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), GenScript, Inc. (US), Integrated DNA Technologies (IDT, US), Nitto Denko Avecia, Inc. (US), TriLink BioTechnologies (US), Biogen International (US), ATDBio Ltd. (UK), Bio-Synthesis, Inc. (US), Eurofins Genomics (Germany), GE Healthcare (US), Sigma-Aldrich Corporation (a part of Merck KGAA, US), and Sarepta Therapeutics (US).